Clinical Trial Update: Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating the utility of F-18 fluoroDOPA for neonatal hyperinsulinism (congenital hyperinsulinism).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Hyperinsulinism
• Hyperinsulinism
• Persistent Hyperinsulinemic Hypoglycemia of Infancy

Drugs mentioned

• [F-18] fluoroDOPA (fluoroDOPA labeled with Fluorine-18)

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Congenital Hyperinsulinism, Hyperinsulinism | Phase 2 | Status: COMPLETED | Results posted: 2022-11-09